Automated, web-based interface reduces the design-build-test cycle by accelerating optimization of large numbers of synthetic DNA constructs in real-time
CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Gen9, Inc., a pioneer in the development of scalable technologies for synthesizing and assembling DNA, today announced the availability of a new, web-based portal powered by Benchling. Through secure access, customers can rapidly and efficiently design or submit DNA sequences, optimize for manufacturing, and track order progress. Benchling is a leading developer of cloud-based tools for life science focused on enabling collaboration and helping researchers increase their productivity.
“We are pleased to be working with Gen9 to empower their customers with tools that simplify the process of accessing high-quality synthetic DNA”
Gen9 has developed unique, next-generation technologies for synthesizing and assembling DNA constructs for use in numerous applications, including antibody and protein engineering, pathway building and genome construction. The company’s proprietary BioFab® platform produces high-quality synthetic DNA constructs at an unprecedented scale.
“Gen9 has already changed the game in gene synthesis with our high-throughput BioFab platform. With the launch of this portal, we’re reinventing the design and ordering process for DNA,” said Kevin Munnelly, President and Chief Executive Officer of Gen9, Inc. “We are enabling our customers to explore more design space and to test more hypotheses, ultimately creating more value for organizations. We have dramatically streamlined DNA construct design and ordering through a unique, multi-parametric batch optimization tool. Now scientists can engineer synthetic genes and pathways faster than ever before.”
Once logged in, a Gen9 customer can easily and securely design, upload, and optimize sequences for parameters such as design for synthesis, codon usage, and cloning strategy. The tool also allows scientists to store, access, and edit sequence information using the Benchling DNA editor, a best-in-class tool that is already being used extensively in the life science industry.
“We are pleased to be working with Gen9 to empower their customers with tools that simplify the process of accessing high-quality synthetic DNA,” said Sajith Wickramasekara, Chief Executive Officer of Benchling. “Benchling is committed to making science more efficient by providing researchers with robust, modern technology that helps them keep pace with the complexity and accelerating speed of biotech R&D. We look forward to our continued partnership with Gen9 as we provide the thousands of scientists using Benchling with additional tools for high-throughput DNA design.”
News of the portal launch was announced at SynBioBeta London, an event where the synthetic biology community gathers to hear from the companies commercializing cutting-edge research.
For more information, please visit www.gen9bio.com/portal.
About Gen9
Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, MA, and can be found online at www.gen9bio.com.
About Benchling
Benchling is a venture-backed company based in San Francisco that aims to increase the rate of scientific output with its cloud-based platform that allows researchers to design and run experiments, analyze data, and share results. Benchling believes an R&D organization should have all institutional knowledge at its fingertips, and that making collaboration seamless will allow science to move faster. The Benchling Research Platform is used by scientists at more than 1,000 institutions around the world. Benchling was launched in 2013 by a team of software engineers with experience in molecular and computational biology whose mission is to help scientists work together. For more information, please visit www.benchling.com.
Gen9, GeneBit, GeneByte and BioFab are trademarks or registered trademarks of Gen9, Inc. All other brands may be trademarks of their respective holders.
Contacts
for Gen9, Inc.
Colin Sanford, 203-918-4347
colin@bioscribe.com
